Show simple item record

dc.contributor.authorJohnston, S
dc.contributor.authorO'Shaughnessy, J
dc.contributor.authorMartin, M
dc.contributor.authorHuober, J
dc.contributor.authorToi, M
dc.contributor.authorSohn, J
dc.contributor.authorAndré, VAM
dc.contributor.authorMartin, HR
dc.contributor.authorHardebeck, MC
dc.contributor.authorGoetz, MP
dc.date.accessioned2021-09-16T10:19:01Z
dc.date.available2021-09-16T10:19:01Z
dc.date.issued2021-06-22
dc.identifier.citationNPJ breast cancer, 2021, 7 (1), pp. 80 - ?
dc.identifier.issn2374-4677
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4807
dc.identifier.eissn2374-4677
dc.identifier.doi10.1038/s41523-021-00289-7
dc.description.abstractIn MONARCH 3, continuous dosing of abemaciclib with an aromatase inhibitor (AI) conferred significant clinical benefit to postmenopausal women with HR+, HER2- advanced breast cancer. We report data for clinically prognostic subgroups: liver metastases, progesterone receptor status, tumor grade, bone-only disease, ECOG performance status, and treatment-free interval (TFI) from an additional 12-month follow-up (after final progression-free survival [PFS] readout). In the intent-to-treat population, after median follow-up of approximately 39 months, the updated PFS was 28.2 versus 14.8 months (hazard ratio [HR], 0.525; 95% confidence interval, 0.415-0.665) in abemaciclib versus placebo arms, respectively. Time to chemotherapy (HR, 0.513), time to second disease progression (HR, 0.637), and duration of response (HR, 0.466) were also statistically significantly prolonged with the addition of abemaciclib to AI. Treatment benefit was observed across all subgroups, as evidenced by objective response rate change from the addition of abemaciclib to AI, with the largest effects observed in patients with liver metastases, progesterone receptor-negative tumors, high-grade tumors, or TFI < 36 months. Extended follow-up in the MONARCH 3 trial further confirmed that the addition of abemaciclib to AI conferred significant treatment benefit to all subgroups, including those with poorer prognosis.
dc.formatElectronic
dc.format.extent80 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleAbemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups.
dc.typeJournal Article
dcterms.dateAccepted2021-05-27
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41523-021-00289-7
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-06-22
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfNPJ breast cancer
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine Therapy Resistance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrine Therapy Resistance
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume7
pubs.embargo.termsNot known
icr.researchteamEndocrine Therapy Resistance
icr.researchteamEndocrine Therapy Resistanceen_US
dc.contributor.icrauthorJohnston, Stephenen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0